The verification and validation of the workflow starts April 2015 at altona Diagnostics, BNITM and INMI. The project partner aim for having the integration of platform and assay as a prototypic system completed until end of March 2015.
The company's products and services focus on cardiology, infectious disease, women's.
ALERE MOLECULAR DIAGNOSTICS PROFESSIONAL
for Alere´s HIV-1/2 Detect cartridges, and altona Diagnostics´ RealStar® Filovirus RT-PCR kit 1.0 a commercial central laboratory real-time PCR test. develops, manufactures and markets consumer and professional medical diagnostic products. We aim to shape the success of genedrive by maintaining a disciplined approach in. no additional equipment and no logistics and storage at -20☌ needed The POC-NAT is based on two already existing technologies: The instrument platform “Alere™q complete” developed and manufactured by Alere, an instrument for POC diagnostics recently used p.e. in Africa, where he held a range of executive posts. process duration from sampling to result less than 45 min 5. assay for specific detection of RNA of all known species from the virus genera Ebola- and Marburgvirus. ready to use cartridge, safely disposable nucleic acid test format with integrated sample preparation 3.
Food and Drug Administration (FDA) for the detection of influenza A and B infection in children and adults. Field proven stand alone, mobile and easy to use instrumentation 2. (NYSE: ALR), a global leader in rapid diagnostics, today announced that its Alere(TM) i Influenza A & B 2 test has received 510(k) marketing clearance from the U.S. The POC-NAT system will have the following features: 1. The company offers its services to molecular diagnostic laboratories, government laboratories, academic institutions, hospitals, genomic research centers. (U.S.), a diagnostic device manufacturer and service provider, which Abbott acquired in October 2017. The project aims for the fast development of a point of care Nucleic Acid Test (POC-NAT) system for filovirus specific RNA, from human sample material, especially from blood samples. The Rapid Diagnostics business is a part of Alere Inc. (NYSE: ALR) announced today a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership. The purpose of this project is to utilize existing and proven PCR assay(s) designed for laboratory use and to take advantage of the Alere™ q point of care molecular instrument and cartridge design to simplify Ebola testing so that molecular testing can be expanded to sites beyond which high end laboratory infrastructure is not available while simultaneously greatly reducing infection risk for the test operator. 1, 2016 / PRNewswire / - Abbott (NYSE: ABT) and Alere Inc. We are proposing to develop a molecular assay for the safe, rapid, specific and sensitive detection of Ebola Virus Infection in capillary (or venous) blood samples combining ALTONA’s Pan-filo screening IVD test with the existing Alere™ q point of care molecular diagnostics platform. Alere i Influenza A & B is the first molecular diagnostic test that delivers actionable, lab-accurate results in less than 15 minutes on a user-friendly platform.
0 kommentar(er)
